Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Niacin

FDA-approved product (capsule, oral), marketed as Niacin, Niacor, Niaspan and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Niacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abdominal pain
  • Acne
  • Anemia (phenotype)
  • Atherosclerosis
  • Cardiovascular disease
  • Chronic kidney disease
  • Coronary artery disease
  • Hypercholesterolemia
  • Hyperlipidemia
  • Iron deficiency anemia
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nicotinic acid and derivatives
FDA pharmacologic class
Nicotinic Acid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Niacin, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae10.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis10.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Niacin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Niacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

    NCT07278492 · start 2026-08-31

    Registered record
    Registry ID
    NCT07278492
    Conditions
    Down Syndrome (DS)
    Interventions
    MIB-626; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-08-31
    Completion
    2028-05-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDown Syndrome (DS)
    InterventionMIB-626; Placebo
    PhasePhase 1
    Registry statusNot yet recruiting

  • NAD Supplementation in Parkinson's Disease

    NCT07703137 · start 2026-08-10

    Registered record
    Registry ID
    NCT07703137
    Conditions
    Parkinson's Disease
    Interventions
    Nicotinamide Riboside (NR); Oral placebo capsules
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-08-10
    Completion
    2027-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionNicotinamide Riboside (NR); Oral placebo capsules
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Study on the Functional Impact of Cosmetics on Improving Self-Esteem and Quality of Life in Black Women

    NCT07618572 · start 2026-03-19

    Registered record
    Registry ID
    NCT07618572
    Conditions
    Post-inflammatory Hyperpigmentation
    Interventions
    Niacinamide and Bioceramide-Based Skincare Regimen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-03-19
    Completion
    2026-10-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-inflammatory Hyperpigmentation
    InterventionNiacinamide and Bioceramide-Based Skincare Regimen
    PhaseNot applicable
    Registry statusRecruiting

  • Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure

    NCT06889142 · start 2025-04

    Registered record
    Registry ID
    NCT06889142
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Nicotinamide Mononucleotide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-04
    Completion
    2025-07
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionNicotinamide Mononucleotide
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

    NCT06280482 · start 2024-03-06

    Registered record
    Registry ID
    NCT06280482
    Conditions
    Smooth Muscle Dysfunction Syndrome (SMDS)
    Interventions
    Nicotinamide riboside (NR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-03-06
    Completion
    2027-07-25
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmooth Muscle Dysfunction Syndrome (SMDS)
    InterventionNicotinamide riboside (NR)
    PhasePhase 1
    Registry statusRecruiting

  • Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

    NCT06073730 · start 2023-11-01

    Registered record
    Registry ID
    NCT06073730
    Conditions
    Elderly AML Patients; Unfit, New-diagnosis AML; Acute Myeloid Leukemia; Venetoclax; Decitabine
    Interventions
    Experimental: Venetoclax in combination with Decitabine (+-sorafenib); Active Comparator: Standard dose of Venetoclax + Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-11-01
    Completion
    2026-04-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionElderly AML Patients; Unfit, New-diagnosis AML; Acute Myeloid Leukemia; Venetoclax +1 more
    InterventionExperimental: Venetoclax in combination with Decitabine (+-sorafenib); Active Comparator: Standard dose of Venetoclax + Azacitidine
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive Age

    NCT05682261 · start 2023-03-23

    Registered record
    Registry ID
    NCT05682261
    Conditions
    Anemia
    Interventions
    UNIMMAP-MMS; IFA; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-03-23
    Completion
    2023-10-17
    Enrolment
    265

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnemia
    InterventionUNIMMAP-MMS; IFA; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Audistim® Day/Night on Hearing Comfort and Patient Quality of Life of Patients With Chronic Tinnitus.

    NCT05300594 · start 2022-03-01

    Registered record
    Registry ID
    NCT05300594
    Conditions
    Tinnitus
    Interventions
    Plant extracts, vitamins and mineral; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-03-01
    Completion
    2023-06-05
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinnitus
    InterventionPlant extracts, vitamins and mineral; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

    NCT03818802 · start 2019-09-16

    Registered record
    Registry ID
    NCT03818802
    Conditions
    Healthy Elderly Volunteers
    Interventions
    Nicotinamide Riboside; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-09-16
    Completion
    2024-11-08
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Elderly Volunteers
    InterventionNicotinamide Riboside; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • The Effectiveness and Safety of Niacinamide 4% and Virgin Coconut Oil 30% for Secondary Prevention of Occupational Hand Dermatitis

    NCT04218500 · start 2019-09-03

    Registered record
    Registry ID
    NCT04218500
    Conditions
    Contact Dermatitis of Hands
    Interventions
    Niacinamide 4%; Virgin Coconut oil 30%
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-09-03
    Completion
    2019-12-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContact Dermatitis of Hands
    InterventionNiacinamide 4%; Virgin Coconut oil 30%
    PhaseNot applicable
    Registry statusCompleted

  • Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma

    NCT05889949 · start 2019-06-01

    Registered record
    Registry ID
    NCT05889949
    Conditions
    Radiomics; Hepatocellular Carcinoma (HCC); Transcatheter Arterial Chemoembolization (TACE); Microvascular Invasion (MVI); Multi-kinase Inhibitors (MKI)
    Interventions
    Sorafenib; Lenvatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-06-01
    Completion
    2023-05-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRadiomics; Hepatocellular Carcinoma (HCC); Transcatheter Arterial Chemoembolization (TACE); Microvascular Invasion (MVI) +1 more
    InterventionSorafenib; Lenvatinib
    PhaseNot recorded
    Registry statusUnknown

  • Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients

    NCT03850886 · start 2019-01-15

    Registered record
    Registry ID
    NCT03850886
    Conditions
    Non Alcoholic Fatty Liver Disease
    Interventions
    Niacinamide Oral Tablet; Antidiabetic
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-01-15
    Completion
    2019-08-07
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Alcoholic Fatty Liver Disease
    InterventionNiacinamide Oral Tablet; Antidiabetic
    PhasePhase 2
    Registry statusCompleted

  • Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

    NCT03812770 · start 2018-08-04

    Registered record
    Registry ID
    NCT03812770
    Conditions
    Hepatocellular Carcinoma
    Interventions
    Sorafenib; HAIC of FOLFOX; HAIC of OXA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-08-04
    Completion
    2019-09-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionSorafenib; HAIC of FOLFOX; HAIC of OXA
    PhasePhase 2
    Registry statusUnknown

  • The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

    NCT02942888 · start 2017-11-30

    Registered record
    Registry ID
    NCT02942888
    Conditions
    Mild Cognitive Impairment; NAD
    Interventions
    Nicotinamide riboside; Sugar Pill
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-11-30
    Completion
    2021-08-16
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Cognitive Impairment; NAD
    InterventionNicotinamide riboside; Sugar Pill
    PhaseNot applicable
    Registry statusCompleted

  • Nicotinamide Riboside and Metabolic Health

    NCT02835664 · start 2016-12

    Registered record
    Registry ID
    NCT02835664
    Conditions
    Obesity; Insulin Resistance
    Interventions
    Nicotinamide Riboside (Niagen); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-12
    Completion
    2018-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Insulin Resistance
    InterventionNicotinamide Riboside (Niagen); Placebo
    PhaseNot applicable
    Registry statusCompleted